Trial record 5 of 37 for:    "Prader-Willi syndrome"

Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome

This study has been completed.
Sponsor:
Information provided by:
Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT00800852
First received: November 30, 2008
Last updated: December 1, 2008
Last verified: November 2008
  Purpose

The inflammatory process is involved in the pathogenesis of obesity. Prader-Willi syndrome (PWS) is a genetic model of syndromic obesity. Adiponectin is an adipokine with potent anti-inflammatory properties, and its effect is mediated through adiponectin receptors 1 (adipoR1) and 2 (adipoR2).

Objective of this study is to compare the expression of adipoR1, adipoR2, and adiponectin in peripheral blood mononuclear cells (PBMCs) in PWS children and obese control and to correlate receptor expression with insulin sensitivity and obesity-related parameters.


Condition
Obesity
Prader-Willi Syndrome

Study Type: Observational
Official Title: Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome

Resource links provided by NLM:


Further study details as provided by Samsung Medical Center:

  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Fourteen children with PWS and control subjects

Criteria

Inclusion Criteria:

  • children with Prader-willi syndrome
  • children with simple obesity

Exclusion Criteria:

  • subjects with diabetes mellitus (fasting plasma glucose > 126 mg/dL with a 2-h oral glucose tolerance test value of >200 mg/dl)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00800852

Sponsors and Collaborators
Samsung Medical Center
Investigators
Principal Investigator: Don-Kyu Jin, M.D. Samsung Medical Center, Sungkyunkwan Uiversity School of Medicine
  More Information

No publications provided

Responsible Party: Dong-Kyu Jin, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT00800852     History of Changes
Other Study ID Numbers: 2008-10-040
Study First Received: November 30, 2008
Last Updated: December 1, 2008
Health Authority: Korea: Food and Drug Administration

Keywords provided by Samsung Medical Center:
adiponectin
adiponectin receptor
Prader-Willi syndrome

Additional relevant MeSH terms:
Prader-Willi Syndrome
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Mental Retardation
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on July 28, 2014